Frequently Asked Questions

Yes. In this 28-day phase 3 randomized, double-blind, placebo-controlled trial, iloperidone was more effective than placebo for reducing manic symptoms in adults with bipolar I disorder. The primary endpoint, change in Young Mania Rating Scale (YMRS) total score from baseline to week 4, was statistically significant in favor of iloperidone. The study authors concluded that 24 mg/day iloperidone demonstrated efficacy for the acute treatment of bipolar mania in adults.

Iloperidone separated from placebo by day 14. The difference in YMRS total score change from baseline was statistically significant on days 14, 21, and 28, but not earlier. The authors noted that this statistical separation was maintained through the remainder of the 4-week double-blind phase.

The study used a fixed dose of 24 mg/day of iloperidone, given as 12 mg twice daily. Patients underwent a 4-day titration using 1 mg, 3 mg, 6 mg, and 9 mg twice-daily doses to reach the target dose. CYP2D6 poor metabolizers received 12 mg/day, given as 6 mg twice daily, consistent with prescribing guidance.

No clear antidepressant effect was shown in this study. Although numerically greater improvement on the Montgomery-Asberg Depression Rating Scale (MADRS) was observed with iloperidone, the change from baseline in MADRS did not reach statistical significance versus placebo at day 28. The authors noted that the trial was not designed to assess patients with moderate to severe depressive symptoms, because baseline MADRS scores had to be below 18.

At day 28, iloperidone also showed statistically significant benefit over placebo on CGI-S, CGI-C, and YMRS responder status. These secondary outcomes supported the primary finding that iloperidone improved acute manic symptoms. Change from baseline in MADRS was the main secondary outcome that did not show a statistically significant difference.

The most common adverse events with iloperidone were tachycardia (17.5%), dizziness (11.2%), dry mouth (9.2%), alanine aminotransferase increased (7.3%), nasal congestion (6.3%), increased weight (5.8%), and somnolence (5.3%). Overall, 67.5% of iloperidone-treated patients had at least 1 adverse event versus 48.6% of placebo-treated patients.

Mean weight increased by 4.60 b1 4.271 kg in the iloperidone group over 28 days, compared with 1.63 b1 3.578 kg in the placebo group. The authors described this as mild to moderate weight gain and noted that it was consistent with prior iloperidone studies in schizophrenia.

Yes, iloperidone was associated with QTcF increase in this study. Mean change in QTcF from baseline to day 28 was +8.3 msec with iloperidone versus -1.0 msec with placebo, and post-randomization QTcF increases of at least 60 msec occurred in 3 iloperidone-treated patients and 0 placebo-treated patients. Ventricular rate also increased more with iloperidone during titration, although by week 4 the average increase was 4.7 beats per minute with iloperidone versus 1.5 beats per minute with placebo.

Orthostatic response was more frequent with iloperidone during titration, but it declined over time and was close to placebo levels later in treatment. At week 4, orthostatic response was observed in 5.6% of iloperidone-treated patients and 4.5% of placebo-treated patients. The authors interpreted this pattern as consistent with adaptation after the early titration period.

Akathisia and extrapyramidal symptoms were generally low with iloperidone in this study. An adverse event of akathisia occurred in 9 patients (4.4%) on iloperidone and in 0 patients on placebo, and no patient discontinued because of akathisia. Rates of extrapyramidal symptoms were otherwise low and similar to placebo, with no statistically significant between-group difference on BARS, SAS, or AIMS change scores.

This was a phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in adults aged 18 to 65 years with bipolar I disorder experiencing a manic episode, with or without mixed features. The double-blind treatment phase lasted 28 days, and all patients were hospitalized during this period to ensure dosing compliance and discontinuation of other antipsychotics. The modified intent-to-treat population included 392 patients, and efficacy was assessed primarily by change in YMRS total score.

Eligible patients were adults aged 18 to 65 years with bipolar I disorder and a current manic episode, with or without mixed features, confirmed by DSM-5-based structured interview. Key entry criteria included a YMRS total score of at least 20, at least 4 points on at least 2 of 4 YMRS items related to irritability, speech, content, or disruptive/aggressive behavior, a CGI-S score of at least 4, and a MADRS total score below 18. Patients were excluded for rapid cycling, major recent substance-related problems, important ECG abnormalities, significant self-harm or violence risk, likely need for ongoing psychotropic drugs such as antidepressants or mood stabilizers, and certain other psychiatric or medical factors.

The main limitations are that the trial excluded patients with significant comorbidities such as substance use disorders and did not assess long-term prevention of manic or depressive episodes. The study also was not designed to evaluate patients with moderate to severe depressive symptoms, which limits interpretation of the MADRS findings. In addition, the randomized treatment period was short, lasting only 28 days.